VERASTEM doses first patient in Phase 2 pancreatic cancer trial

June 16, 2026 4:01 PM

Verastem Oncology (NASDAQ: VSTM) announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found